Spots Global Cancer Trial Database for PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
Official Title: PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy
Study ID: NCT03314805
Study Description
Brief Summary: Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence. Anthracycline-based regimens, including doxorubin or epilubicin, are the breast cancer adjuvant chemotherapy standards of care. Fatigue has also been identified as the most problem for breast cancer patients under adjuvant chemotherapy. In the current study, it is aimed to show that PG2 (astragalus polysaccharides) treatment among stage II/III breast patients under adjuvant EC regimen in reduction of chemotherapy-induced toxicity and encouraging compliance with chemotherapy.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
E-Da Cancer Hospital, Kaohsiung City, , Taiwan
Chang Gung Memorial Hospital, Kaohsiung Branch, Kaohsiung City, , Taiwan
Chang Gung Memorial Hospital, Lakeview Branch, Keelung, , Taiwan
Chang Gung Memorial Hospital, Taipei Branch, Taipei, , Taiwan
Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, , Taiwan
Contact Details
Name: Kun-Ming Rau, MD
Affiliation: E-Da Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
